IMS 2022 | The importance of genetic testing in high-risk multiple myeloma & targeted therapy

Martin Kaiser, MD, FRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, emphasizes the importance of genetic testing and monitoring in patients with high-risk multiple myeloma, outlining different techniques that can be used to identify cytogenetic aberrations, and commenting on optimizing treatment based on a patient’s genomic profile. It has been shown that patients with co-occurrence of two or more high-risk cytogenetic aberrations (15%) have worse outcomes than other patients. It is therefore essential to conduct genetic testing to identify those patients early and closely monitor them to detect early relapse. Dr Kaiser highlights methods that do not require a lot of genetic material including multiplex ligation-dependent probe amplification (MLPA) to detect cytogenetic aberrations. Detecting these lesions will allow patients to receive more intensified consolidation and maintenance therapy and eventually improve their outcomes. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.